EIF(ISO)4G2 Antibody

What is the 4G2 antibody and what specific epitope does it recognize?

The 4G2 antibody (clone D1-4G2-4-15) is a monoclonal antibody that recognizes a highly conserved epitope on the envelope (E) protein of viruses in the Flavivirus family. Specifically, it binds to the fusion loop at the extremity of domain II of the E protein. This epitope is functionally important as it plays a role in viral fusion with host cell membranes during infection . The conservation of this epitope across multiple flaviviruses makes the 4G2 antibody particularly valuable as a pan-flavivirus detection reagent. The binding characteristics have been extensively analyzed by Crill and Chang (2004), who mapped and characterized the cross-reactive epitopes on flavivirus envelope glycoproteins . The antibody has demonstrated the ability to prevent syncytia formation in infected cells, suggesting its potential function in neutralizing viral activity through interference with the fusion mechanism .

Which flaviviruses can be detected using the 4G2 antibody?

The 4G2 antibody demonstrates broad cross-reactivity across the Flaviviridae family due to its recognition of a highly conserved epitope. Based on validated experimental evidence, the 4G2 antibody has been confirmed to recognize several significant human pathogens including:

• Dengue virus (all serotypes)

• West Nile virus

• Japanese Encephalitis virus

• Zika virus

• Yellow Fever virus

This extensive cross-reactivity is attributed to the conservation of the fusion loop epitope within domain II of the envelope protein across flaviviruses. Researchers should note that while this broad reactivity makes 4G2 an excellent screening tool, it necessitates additional confirmatory methods when specific virus identification is required. The antibody has been experimentally validated through multiple techniques including ELISA, immunofluorescence, Western blotting, and flow cytometry across these viruses .

What formats of the 4G2 antibody are available for research applications?

The 4G2 antibody is available in multiple formats to accommodate diverse experimental needs and research applications:

• Species variations:

  • Mouse IgG2a (original format)

  • Human IgG1 (chimerized version)

  • Human IgM

  • Mouse IgM

  • Rabbit IgG

  • Ferret IgG1, IgM, and IgA

  • Cynomolgus monkey IgG1

  • Goat IgG

• Functional modifications:

  • Standard formats

  • Fc Silent™ versions (reduced Fc receptor binding)

  • LALA mutants (reduced Fc-mediated effects)

• Fluorophore conjugates:

  • Alexa Fluor™ 647 conjugated format for flow cytometry and microscopy applications

These diverse formats enable researchers to select the most appropriate antibody version based on specific experimental requirements, host species compatibility, and desired detection methods. The human IgG1 version has been engineered through chimerization from the original mouse monoclonal, retaining the original variable domains while replacing constant regions with human IgG1 sequences .

Which experimental techniques can effectively utilize the 4G2 antibody?

The 4G2 antibody has been validated for multiple experimental techniques in flavivirus research, making it a versatile tool for various applications:

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • The antibody has been successfully used in antigen-capture ELISA systems for flavivirus detection

  • Demonstrated effectiveness with Dengue virus-like particles (VLPs) in ELISA format

  • Can function as a detection antibody in IgM-capture ELISA with enhanced sensitivity

• Western Blotting:

  • Effective for detecting flavivirus envelope proteins under denaturing conditions

  • Recognizes a linear epitope that remains accessible after SDS-PAGE processing

• Flow Cytometry:

  • Available in fluorophore-conjugated formats (e.g., Alexa Fluor 647) for cellular analysis

  • Useful for detecting infected cells and quantifying infection rates

• Neutralization Assays:

  • Applied in virus neutralization studies to assess antibody function

  • Can prevent syncytia formation in cellular infection models

• Immunofluorescence:

  • Suitable for detection of viral antigens in fixed cells and tissues

  • Compatible with various secondary detection systems

The antibody has greater than 95% purity by SDS-PAGE and is typically buffered in PBS at pH 7.4 for optimal stability and performance across these applications .

How can researchers address potential antibody-dependent enhancement (ADE) when using 4G2 in flavivirus studies?

Antibody-dependent enhancement (ADE) is a critical consideration when working with flavivirus antibodies, particularly in Dengue virus research. The 4G2 antibody, while useful for detection and neutralization studies, can potentially contribute to ADE phenomena in certain experimental contexts:

• Mechanism of concern:

  • The 4G2 antibody binds to the fusion loop epitope but may not fully neutralize all virus particles

  • Sub-neutralizing concentrations can promote enhanced infection of Fc receptor-bearing cells

  • This may complicate interpretation of in vitro and in vivo infection studies

• Methodological approaches to address ADE:

  • Titration optimization: Carefully determine optimal antibody concentrations for neutralization versus enhancement windows

  • Fc modification: Utilize the available Fc Silent™ or LALA mutant versions (Ab00230-10.3, Ab00230-10.16, Ab00230-2.3) which have reduced Fc-mediated functions while maintaining antigen binding

  • Control experiments: Include appropriate isotype controls and Fc receptor blocking conditions

  • Cell selection: Consider the Fc receptor status of cell lines used in experiments

• Experimental validation:

  • Conduct parallel experiments with both wild-type and Fc-modified antibody variants

  • Measure infection rates using flow cytometry or plaque assays under different antibody concentrations

  • Include appropriate controls for Fc receptor-mediated effects

By implementing these methodological approaches, researchers can distinguish between direct antiviral effects and potential enhancement phenomena when using the 4G2 antibody in flavivirus research systems .

What are the optimal conditions for using 4G2 in multiplex immunoassays for flavivirus differential diagnosis?

Developing multiplex immunoassays for differential diagnosis of flavivirus infections requires careful optimization of the 4G2 antibody application:

• Cross-reactivity management:

  • The 4G2 antibody recognizes a conserved epitope across multiple flaviviruses, making it valuable as a group-reactive reagent

  • For differential diagnosis, pair 4G2 with virus-specific antibodies targeting unique epitopes

  • Consider a two-step approach: first screening with 4G2, then confirming with virus-specific antibodies

• Assay development parameters:

  • Buffer optimization: PBS at pH 7.4 is standard, but additional blocking agents may be needed to minimize background

  • Antibody concentration: Titrate to determine optimal concentration (typically 1-10 μg/ml) for specific detection platforms

  • Sample type considerations: Different pretreatment protocols may be needed for serum versus tissue samples

• Multiplex platform considerations:

  • Bead-based systems: Label different antibody sets on distinct bead populations

  • Microarray formats: Spatial separation of capture antibodies

  • Detection strategy: Consider using 4G2 as a capture antibody with virus-specific detection antibodies or vice versa

• Validation protocols:

  • Test with reference samples containing known flaviviruses individually and in mixtures

  • Establish standard curves for semi-quantitative analysis

  • Determine limits of detection and quantification for each virus type

  • Evaluate potential interference between detection channels

By carefully optimizing these parameters, researchers can develop robust multiplex assays that leverage the broad reactivity of 4G2 while achieving the specificity needed for differential diagnosis of flavivirus infections .

What strategies can improve detection sensitivity when using 4G2 antibody in flavivirus diagnostic assays?

Enhancing detection sensitivity is crucial for early diagnosis and low-titer samples in flavivirus research. Several methodological approaches can improve 4G2 antibody-based assay sensitivity:

• Signal amplification strategies:

  • Avidin-biotin systems: Biotinylate 4G2 and use streptavidin-conjugated enzymes or fluorophores for signal multiplication

  • Polymer detection systems: Employ antibody-conjugated polymers carrying multiple enzyme or fluorophore molecules

  • Tyramide signal amplification: Utilize peroxidase-catalyzed deposition of labeled tyramide for enhanced signal

  • Quantum dots: Consider quantum dot conjugates for higher quantum yield and photostability

• Sample preparation optimization:

  • Viral concentration: Implement ultracentrifugation or polyethylene glycol precipitation for low-titer samples

  • Detergent optimization: Carefully select detergents that expose the 4G2 epitope without disrupting antibody binding

  • Heat treatment: Controlled sample heating may improve epitope accessibility in some contexts

• Assay format enhancements:

  • Capture antibody orientation: Test both direct coating and capture antibody approaches

  • Incubation conditions: Optimize temperature, time, and agitation parameters

  • Sequential versus simultaneous incubations: Compare detection limits of different incubation strategies

• Validated enhancements from literature:

  • Nawa et al. (2001) demonstrated significantly improved sensitivity in dengue IgM-capture ELISA by employing the 4G2 monoclonal antibody as a detection reagent compared to polyclonal alternatives

  • Temperature cycling during incubation has shown improved binding kinetics in some antibody-based assays

By systematically implementing and evaluating these enhancement strategies, researchers can achieve optimal sensitivity when using the 4G2 antibody for flavivirus detection in various diagnostic platforms .

How can researchers overcome epitope masking issues when using 4G2 in complex biological samples?

Epitope masking can significantly impact 4G2 antibody performance in complex biological samples. This methodological challenge can be addressed through several research-validated approaches:

• Sample pretreatment protocols:

  • Mild denaturation: Brief heat treatment (56°C for 30 minutes) can disrupt protein-protein interactions without destroying epitopes

  • pH adjustment: Temporary exposure to mildly acidic conditions (pH 5.0-6.0) followed by neutralization can unmask certain epitopes

  • Selective detergents: Mild detergents like 0.1% Triton X-100 or 0.05% Tween-20 can disrupt lipid structures while preserving protein epitopes

  • Enzymatic treatment: Selective use of proteases (e.g., pepsin, trypsin) at controlled concentrations can remove masking proteins

• Buffer optimization strategies:

  • Ionic strength adjustment: Higher salt concentrations may reduce non-specific protein interactions

  • Blocking agent selection: Test multiple blocking agents (BSA, casein, gelatin) to identify optimal formulations

  • Additives evaluation: Include compounds like polyethylene glycol, glycerol, or specific divalent cations to modify protein-protein interactions

• Alternative epitope targeting:

  • Combine 4G2 with antibodies targeting different epitopes for comprehensive detection

  • Sequential application of different antibodies may access previously masked sites

• Validation approaches:

  • Compare recovery rates from spiked samples using different pretreatment protocols

  • Analyze epitope accessibility by comparing native versus denatured sample detection

  • Include internal controls with known epitope exposure characteristics

By systematically evaluating these methodological approaches, researchers can optimize protocols to overcome epitope masking challenges when using the 4G2 antibody in complex biological samples such as serum, plasma, or tissue homogenates .

How can the 4G2 antibody be effectively utilized in quantitative studies of antibody-dependent enhancement (ADE) mechanisms?

Antibody-dependent enhancement (ADE) is a critical phenomenon in flavivirus pathogenesis, particularly for dengue virus infections. The 4G2 antibody provides a valuable tool for investigating ADE mechanisms when used with appropriate methodological controls:

• Experimental system design:

  • Cell selection: Use well-characterized Fc receptor-bearing cells (e.g., K562, U937, THP-1) with confirmed receptor expression levels

  • Virus preparation: Standardize virus stocks by plaque assay or RNA quantification

  • Antibody titration: Establish a complete dilution series from neutralizing to sub-neutralizing concentrations

• Quantitative measurement approaches:

  • Flow cytometry: Measure infection rates using intracellular staining of viral antigens

  • Plaque reduction neutralization test (PRNT): Compare plaque numbers with and without Fc receptor blockade

  • Quantitative RT-PCR: Monitor viral replication kinetics under different antibody conditions

  • Luminescent reporter viruses: Utilize engineered reporter flaviviruses for high-throughput quantification

• Controlled comparison methodology:

  • Parallel testing of wild-type 4G2 versus Fc-modified variants (Silent™ or LALA mutants)

  • Inclusion of isotype controls and non-binding antibody controls

  • Fc receptor blockade conditions using anti-FcR antibodies or soluble Fc fragments

  • Comparative analysis across multiple flavivirus species

• Data analysis framework:

  • Calculate enhancement indices (ratio of infection with antibody versus without)

  • Determine peak enhancement concentrations and neutralization concentrations

  • Construct mathematical models of enhancement kinetics

  • Correlate enhancement with structural and functional antibody characteristics

Through careful experimental design and quantitative analysis, researchers can use the 4G2 antibody as both a model enhancing antibody and a flavivirus detection tool to dissect the complex mechanisms of antibody-dependent enhancement in flavivirus infections .

What are the latest approaches for applying 4G2 in cryo-electron microscopy studies of flavivirus structure and antibody binding?

Cryo-electron microscopy (cryo-EM) has revolutionized structural studies of viruses, and the 4G2 antibody provides valuable capabilities for investigating flavivirus envelope structures through this technique:

• Sample preparation optimization:

  • Antibody fragment generation: Convert 4G2 to Fab fragments to reduce flexibility and improve resolution

  • Complex formation: Incubate purified virus particles with 4G2 antibody at optimized ratios (typically 1:3 to 1:10 molar ratio)

  • Grid preparation: Test multiple vitrification conditions to identify optimal ice thickness and particle distribution

  • Time-staged binding: Capture different states of the binding interaction through time-course experiments

• Data collection strategies:

  • Particle classification: Implement computational approaches to sort particles by antibody occupancy

  • Focused classification: Use mask-based classification to enhance resolution of the antibody-binding region

  • Local refinement: Apply local refinement techniques to the epitope-paratope interface

  • Time-resolved studies: Consider time-resolved cryo-EM for capturing conformational changes upon antibody binding

• Structural analysis approaches:

  • Epitope mapping: Compare bound versus unbound virus structures to identify conformational changes

  • Antibody binding angles: Analyze the geometric relationship between antibody and virus surface

  • Stoichiometry assessment: Determine the number of antibodies bound per virus particle

  • Fusion loop conformation: Focus analysis on how antibody binding affects the fusion loop structure

• Integration with complementary techniques:

  • Correlate cryo-EM structures with neutralization or enhancement functional data

  • Combine with molecular dynamics simulations to model binding energetics

  • Validate findings through site-directed mutagenesis of key residues

By implementing these advanced methodological approaches, researchers can utilize the 4G2 antibody to gain unprecedented insights into flavivirus structure, epitope accessibility, and the molecular mechanisms of antibody-mediated neutralization or enhancement .

What are the emerging research applications for the 4G2 antibody beyond traditional diagnostic and structural studies?

The 4G2 antibody is finding novel applications in cutting-edge flavivirus research beyond its traditional roles in diagnostics and structural biology:

• Therapeutic development platforms:

  • Antibody engineering: The 4G2 antibody serves as a template for developing improved therapeutic antibodies through techniques like affinity maturation and framework modification

  • Bispecific antibody design: Combining 4G2 binding domains with other functional domains creates novel molecules with multiple targeting capabilities

  • Antibody-drug conjugates: 4G2 can direct cytotoxic payloads specifically to flavivirus-infected cells

  • Chimeric antigen receptor (CAR) development: The binding domain of 4G2 can be incorporated into CARs for cellular immunotherapy approaches targeting flavivirus infections

• Advanced imaging applications:

  • Super-resolution microscopy: Fluorophore-conjugated 4G2 enables nanoscale visualization of viral envelope distribution

  • Intravital imaging: Using 4G2 to track flavivirus dissemination in living tissues

  • Correlative light and electron microscopy (CLEM): Combining fluorescent 4G2 labeling with electron microscopy for multiscale analysis

• Fundamental virology research:

  • Virus-cell interaction studies: Tracking envelope protein dynamics during cell entry and fusion

  • Viral maturation analysis: Monitoring conformational changes in the envelope protein during virus assembly

  • Cross-species transmission studies: Comparing envelope protein conservation across emerging flaviviruses

• Biotechnology applications:

  • Affinity purification: Using immobilized 4G2 for purification of flavivirus particles or envelope proteins

  • Biosensor development: Incorporating 4G2 into advanced detection platforms for environmental monitoring

  • Quality control for vaccine production: Validating envelope protein content and conformation in vaccine preparations

These emerging applications demonstrate the continuing value of the 4G2 antibody as a research tool, even as more specific antibodies are developed for individual flaviviruses .

How should researchers interpret conflicting results when comparing 4G2 antibody data with virus-specific antibody findings?

Interpreting discrepancies between data generated with the cross-reactive 4G2 antibody versus virus-specific antibodies requires careful methodological consideration:

• Epitope-based analysis framework:

  • The 4G2 antibody targets the fusion loop epitope in domain II, while virus-specific antibodies often target other regions such as domain III or complex conformational epitopes

  • Different epitopes may be accessible to varying degrees depending on virus maturation state, pH conditions, and sample preparation methods

  • Map discrepancies to structural differences in the target epitopes through comparative epitope modeling

• Methodological approach to resolving conflicts:

  • Parallel testing: Analyze samples simultaneously with both antibody types under identical conditions

  • Sequential epitope exposure: Test whether sample pretreatment differentially affects epitope accessibility

  • Virus maturation state: Determine whether conflicts correlate with the maturation status of virus particles

  • Competitive binding assays: Use labeled antibodies to assess whether binding is mutually exclusive or cooperative

• Technical validation strategies:

  • Independent detection methods: Confirm findings using orthogonal techniques (e.g., PCR, mass spectrometry)

  • Antibody characterization: Verify antibody specificity and sensitivity through controlled experiments

  • Epitope mutation studies: Introduce targeted mutations to confirm epitope specificity

  • Interlaboratory validation: Compare results across different research groups

• Interpretation framework:

  • Construct a decision tree for interpreting conflicting results based on assay conditions

  • Consider antibody characteristics including affinity, avidity, and potential cross-reactivity

  • Evaluate the biological significance of each epitope in virus lifecycle and pathogenesis

  • Develop an integrated model that reconciles apparently conflicting observations